Phase I/II clinical trial of WT1 peptide vaccine therapy for lung, breast, pancreas, stomach, and colorectal cancer
Phase 1
- Conditions
- ung, breast, pancreas, stomach, and colorectal cancer
- Registration Number
- JPRN-UMIN000011029
- Lead Sponsor
- Shinshu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with severe organ dysfunction, infection under treatment, blood abnormalities or bleeding tendency. 2.Patients fulfilling the criteria of WT1 pulsed dendritic cell therapy are excluded from this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <Phase I portion> Ratios of adverse events <Phase II portion> PFS: Progression free survival, Overall survival
- Secondary Outcome Measures
Name Time Method <Phase I portion> WT1 specific CTL rate in peripheral blood mononuclear cells (PBMCs), Lymphocyte subsets, WT1-specific interferon(IFN)-gamma production of PBMCs <Phase II portion> The ratio of the patients who completed the course, WT1 specific CTL rate in PBMCs, Lymphocyte subsets, WT1-specific IFN-gamma production of PBMCs